Clinical trials

Filters
Clear filters
10 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757Alkermes, Inc.Phase 3Completed2023-09-06Actual
Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229Alkermes, Inc.Phase 3Enrolling by invitation2027-09Estimated
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Alkermes, Inc.Phase 3Recruiting2027-12Estimated
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950Alkermes, Inc.Phase 2Completed2025-06-19Actual
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2NCT06555783Alkermes, Inc.Phase 2Completed2025-11-11Actual
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683Alkermes, Inc.Phase 2, Phase 3Recruiting2030-06Estimated
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590Alkermes, Inc.Phase 2Active not recruiting2026-11Estimated
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1NCT07455383Alkermes, Inc.Phase 3Recruiting2027-05Estimated
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443Alkermes, Inc.Phase 3Recruiting2027-05Estimated
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)NCT07540897Alkermes, Inc.Phase 3Recruiting2027-06Estimated

Primary completion marks the end of data collection for the main study measures, not a results publication date.